Amyotrophic Lateral Sclerosis Market Research Report - Forecast to 2027

Amyotrophic Lateral Sclerosis Market Research Report: By Type (Familial ALS), by Treatment (Medication, Physical Therapy, Speech Therapy), by Diagnosis (Laboratory Tests, Imaging Tests), End-User (Hospitals, Specialty Centers)- Forecast till 2027

ID: MRFR/Pharma/4366-CR | | Region: Global | 115 pages

Amyotrophic Lateral Sclerosis Market Overview:


Amyotrophic lateral sclerosis (ALS) belongs to a group of rare neurological disorders. This neurodegenerative disease badly impacts the nerve cells in the brain and the spinal cord. Also known as motor neuron diseases, they affect the motor functions of voluntary muscles in the body. Symptoms of ALS include muscle twitching and muscles decreasing in size. Factors such as an increase in the incidence rate of ALS, rise in the awareness about the disease among patients, and rise in the geriatric population is expected to boost the growth of the amyotrophic lateral sclerosis market.


The Global ALS market valuation is expected to surpass USD 841.6 million by 2023, growing at approximately 7.89 % CAGR over the forecast period (2018-2023). In 2017, the amyotrophic lateral sclerosis market had a valuation of USD  526 million.


Additional factors such as the inclination towards the sedentary lifestyle are driving the market growth and increasing the risk of developing ALS. Besides, the increasing geriatric population substantiates market growth, creating a demand for symptomatic and targeted treatment options. 


But the high cost of the treatment of ALS may hinder the market growth over the forecast period.


Segmentation Analysis


The Global amyotrophic lateral sclerosis market has been segmented on the basis of type, treatment, and end-user.


By type, the market is segmented into sporadic and familial ALS. The sporadic ALS, also abbreviated as SALS, was the largest segment in 2017 and can dominate the market over the forecast period.


By treatment, the amyotrophic lateral sclerosis market has been segmented into medication, physical therapy, respiratory therapy, speech therapy, and others. Out of these, medication had the largest market in 2017.


By end-user, the ALS market has been segmented into hospitals, specialty centers, research & academic institutes, and others. Among these, the subsegment Hospital accounts for the largest segment.


Regional Analysis


By Regions, the global amyotrophic lateral sclerosis market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa. 


The Americas is estimated to dominate the global amyotrophic lateral sclerosis market owing to the increasing pool of awareness and the rising prevalence of hypertension. ALS remains a significant public health challenge in the US. Therefore, governments and private non-profit organizations are developing specific guidelines for the management and treatment of ALS. Public and private organizations are involved in strategic partnerships and collaborations in search for a better outcome in the research of amyotrophic lateral sclerosis treatment in the region.


The amyotrophic lateral sclerosis market in the European region stands at the second position in terms of the market size mainly due to the well-established healthcare sector. Several companies and research institutes are also establishing advanced facilities to research ALS.


Moreover, in recent years, there has been an increase in the adoption of sedentary lifestyles among people. Research shows that an increase in physical activities such as exercise helps in reducing the pain and thwarting some of the symptoms such as loss of motion in patients who have ALS.


Thus, the inclination towards the sedentary lifestyle increases the risk of developing ALS among the elderly population, thus creating a demand for symptomatic and targeted treatment options. The development of novel therapeutic approaches and advanced treatment options are likely to push the growth of the amyotrophic lateral sclerosis market during the forecast period.


Whereas, the amyotrophic lateral sclerosis market in the Asia Pacific region is expected to grow rapidly due to the increasing prevalence of the disease and rapidly developing healthcare infrastructure. The increasing economy in the region is playing a vital role in the growth of the market. Furthermore, the increase in the setups of research and development centers also fuels the growth of the ALS market in the region.


Amyotrophic Lateral Sclerosis Market Key Players


Market players profiled in the amyotrophic lateral sclerosis global market report are Sun Pharmaceutical (India), Mitsubishi Tanabe Pharma America (U.S.), Biogen (U.S.), Sanofi (France), Mylan N.V. (U.S.), Covis Pharma (Switzerland), Ionis Pharmaceutical (U.S.), ITF Pharma (U.S.), Ascend Pharmaceuticals LLC (U.S.), Apotex Inc. (Canada), and others.


Research Methodology


The research report global amyotrophic lateral sclerosis market comprises in-depth primary research and the detailed analysis of qualitative and quantitative aspects of various market experts. Key opinions of market leaders enable to gain a deeper insight into the performance of the market. The blow by blow detailed market analysis gives a clear picture of the current market scenarios including past and future market size in terms of value as well as volume alongside the technological advancement, macroeconomic factors, and governing factors of the market. The report provides detailed information and strategies of top-notch players in the market while providing a broad study of the market’s various segments.


Analysis Period:

  • Base Year - 2017

  • Projection Period - 2018 to 2023

  • Market Valuation - USD Million


For the scope of comprehension, the global amyotrophic lateral sclerosis market is segmented in the following manner.


Type:



  • Sporadic ALS (SALS)

  • Familial ALS (FALS)


Treatment:



  • Medication

  • Physical Therapy

  • Respiratory Therapy

  • Speech Therapy

  • Others


End-user:



  • Hospitals

  • Specialty Centers

  • Research & Academic Institutes

  • Others


Region:



  • Americas

    • The U.S.

    • Canada




    • North America

    • Latin America




  • Europe

    • France

    • The U.K.

    • Germany

    • Italy

    • Spain

    • Rest of Western Europe




    • Western Europe

    • Eastern Europe




  • Asia Pacific


    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia Pacific




  • Middle East & Africa

    • The Middle East

    • Africa





Report Scope:
Report Attribute/Metric Details
  Market Size   2023: USD 841.6 million
  CAGR   2018-2023: 7.89%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment and End-User
  Geographies Covered   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Key Vendors   Sun Pharmaceutical (India), Mitsubishi Tanabe Pharma America (U.S.), Biogen (U.S.), Sanofi (France), Mylan N.V. (U.S.), Covis Pharma (Switzerland), Ionis Pharmaceutical (U.S.), ITF Pharma (U.S.), Ascend Pharmaceuticals LLC (U.S.), Apotex Inc. (Canada)
  Key Market Opportunities   Developing healthcare infrastructure
  Key Market Drivers

  • Rise in the awareness about the disease among patients
  • Rise in the geriatric population


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The treatments included in Amyotrophic Lateral Sclerosis Market are medication, physical therapy, respiratory therapy, speech therapy.

    Various tests included in the ALS Market are Laboratory Tests, Imaging Tests and Others

    Hindering factor of the Amyotrophic Lateral Sclerosis Market would be its high treatment cost.

    Amyotrophic Lateral Sclerosis Market would be led by the hospital segment.

    Valuation of the Amyotrophic Lateral Sclerosis Market would be around USD 841.6 million by 2023.

    Amyotrophic Lateral Sclerosis Market would grow with a CAGR of 7.89% during the forecast period of 2020 to 2027.

    Amyotrophic Lateral Sclerosis Market Research Report - Summary


    Overview:


    Amyotrophic lateral sclerosis (ALS) is a rare progressive disease that affects the nerve cells in the brain and the spinal cord that controls voluntary muscles. In recent years, there has been a noticeable increase in the sedentary lifestyle which results in the increasing the risk of developing ALS among the populace.


    Factors such as the increasing incidence of ALS, growing elderly population, and the rising awareness about ALS are expected to boost the growth of the global amyotrophic lateral sclerosis market over the assessment period creating a demand for symptomatic and targeted treatment options.


    Simultaneously, therapy development activities that have constantly been growing, led by substantial funding from the public and private organizations are supporting the market growth. Moreover, factors such as the increasing research in the management and treatment of amyotrophic lateral sclerosis, and the growing awareness about the severity of the disease is expected to drive the market growth.


    But the high cost associated with ALS treatment could stymie the ALS market growth during the forecast period.


    Segmentation


    The global amyotrophic lateral sclerosis market has been segmented on the basis of type, treatment, end-user, and regions.


    By type, the market is segmented into sporadic ALS and familial ALS. The Sporadic ALS is the largest segment mainly due to its high prevalence. More than 90% of the total ALS cases are Sporadic ALS. Although, the cause of sporadic ALS is not well understood, a combination of environmental and genetic risk factors is considered for developing its symptoms. Whereas, only around 5-10% of cases are familial ALS and caused due to the genetic mutations and are inherited from a family member.


    By treatment, the global amyotrophic lateral sclerosis market has been segmented into medication, physical therapy, respiratory therapy, speech therapy, and others. Out of these, medication accounted for the largest share. Medication is the most effective hence, more preferred and prevalent segment in the line of treatment.  


    By end-user, the ALS market has been segmented into hospitals, specialty centers, research & academic institutes, and others. Among these, the subsegment hospital accounted for the largest share. Hospitals being the first point of treatment can dominate the global market owing to being preferred by most patients.


    Regional Analysis


    The Americas region dominates the global amyotrophic lateral sclerosis market mainly due to higher health care expenditures and the increasing prevalence of ALS among the growing population.


    The Europe amyotrophic lateral sclerosis market has assumed the second position globally, due to the rise in the research labs established to discover breakthrough therapeutics to treat ALS.


    The amyotrophic lateral sclerosis market in the Asia Pacific region is expected to emerge as a promising market, growing rapidly due to the increasing prevalence of ALS, rapidly developing healthcare infrastructure, and improving economic conditions in the region.


    The Middle East and Africa region is expected to witness steady growth due to limited access and healthcare affordability among the population. Rising awareness regarding health and availability of new treatment methods are expected to drive the market in this region. The local drug manufacturing companies in the Gulf regions represent a poor outlook in terms of drugs and depend mainly on imports. Many pharmaceutical companies are targeting these developing and underdeveloped regions for their strategic expansions.


    Competitive Analysis


    Prominent players operating in the Amyotrophic Lateral Sclerosis market include Abbott, B. Braun Melsungen AG, Boston Scientific Corporation, Cook Medical, Medtronic Plc, and others.


    The global amyotrophic lateral sclerosis market has witnessed moderate degrees of competition. Major players operating in the market are opting for new product launches, strategic collaborations, and partnerships to hold onto their position in the market.


    Pharmaceutical companies are trying to develop products with high quality and enhanced safety to increase the demand for the medicines in the developed as well as developing region. Other factors influencing the investment opportunity in the market include rising competition among players, profitability, and potential growth opportunities.


    There is a profitable investment opportunity for existing players and as well as new entrants. Most of the market participants are focusing on the development of bioresorbable stents considering the augmenting demand in the market which is expected to grow in the coming years.


    These players are focusing on increasing their R&D and manufacturing activities by acquiring promising companies engaged in manufacturing bioresorbable stents. Moreover, the adoption of price control strategy provides an excellent opportunity for new entrants to introduce their technologies at low cost in the growing markets in the APAC region to capture profitable share.

    1 Executive Summary

    2 Market Introduction

    2.1 Definition 17

    2.2 Scope of the Study 17

    2.3 List of Assumptions 17

    2.4 Market Structure 18

    3 Research Methodology

    3.1 Research Process 20

    3.2 Primary Research 21

    3.3 Secondary Research 22

    3.4 Market Size Estimation 23

    3.5 Forecast Model 23

    4 Market Dynamics

    4.1 Overview 25

    4.2 Drivers 26

    4.2.1 Growing Incidence of Amyotrophic Lateral Sclerosis (ALS) 26

    4.2.2 Rising Geriatric Population 26

    4.2.3 Growing Awareness about Amyotrophic Lateral Sclerosis 26

    4.3 Restraints 27

    4.3.1 High Cost of ALS Treatment 27

    4.4 Opportunities 27

    4.4.1 Increasing Strategic Collaborations of Major Companies and Research Institutes for the Development of ALS Treatment 27

    5 Market Factor Analysis

    5.1 Porter’s Five Forces Model 29

    5.1.1 Bargaining Power of Suppliers 30

    5.1.2 Bargaining Power of Buyers 30

    5.1.3 Threat of New Entrants 30

    5.1.4 Threat of Substitutes 30

    5.1.5 Intense Rivalry 30


    5.2 Value Chain Analysis 31

    5.2.1 Raw Material Sourcing 31

    5.2.2 Manufacturing 31

    5.2.3 Distribution & Sales 31

    5.2.4 Post-Sales Monitoring 32

    5.3 Investment Feasibility Analysis 32

    5.4 Pricing Analysis 32

    6 Global Amyotrophic Lateral Sclerosis Market, by Type

    6.1 Overview 34

    6.2 Sporadic ALS 34

    6.3 Familial ALS 35

    7 Global Amyotrophic Lateral Sclerosis Market, by Treatment

    7.1 Overview 37

    7.2 Medication 38

    7.3 Physical Therapy 39

    7.4 Respiratory Therapy 39

    7.5 Speech Therapy 40

    7.6 Others 40

    8 Global Amyotrophic Lateral Sclerosis Market, by End User

    8.1 Overview 42

    8.2 Hospitals 42

    8.3 Specialty Centers 43

    8.4 Research and Academic Institutes 44

    8.5 Others 44

    9 Global Amyotrophic Lateral Sclerosis Market, by Region

    9.1 Overview 46

    9.2 Americas 47

    9.2.1 North America 49

    9.2.1.1 US 51

    9.2.1.2 Canada 53

    9.2.2 Latin America 54

    9.3 Europe 56

    9.3.1 Western Europe 58

    9.3.1.1 Germany 61

    9.3.1.2 France 62

    9.3.1.3 UK 64

    9.3.1.4 Italy 65

    9.3.1.5 Spain 67

    9.3.1.6 Rest of Western Europe 68

    9.3.2 Eastern Europe 70

    9.4 Asia-Pacific 72

    9.4.1 Japan 74

    9.4.2 Australia 76

    9.4.3 China 77

    9.4.4 India 79

    9.4.5 South Korea 80

    9.4.6 Rest of Asia-Pacific 82

    9.5 Middle East & Africa 84

    9.5.1 Middle East 86

    9.5.2 Africa 88

    10 Company Landscape

    10.1 Overview 91

    10.2 Company Ranking 91

    11 Company Profile

    11.1 Ascend Laboratories LLC 94

    11.1.1 Company Overview 94

    11.1.2 Financial Overview 94

    11.1.3 Products/Services Offered 94

    11.1.4 SWOT Analysis 95

    11.1.5 Key Developments 95

    11.1.6 Key Strategy 95

    11.2 Apotex Inc. 96

    11.2.1 Company Overview 96

    11.2.2 Financial Overview 96

    11.2.3 Products/Services Offered 96

    11.2.4 SWOT Analysis 96

    11.2.5 Key Developments 96

    11.2.6 Key strategy 96


    11.3 Biogen 97

    11.3.1 Company Overview 97

    11.3.2 Financial Overview 97

    11.3.3 Products/Services Offered 98

    11.3.4 SWOT Analysis 98

    11.3.5 Key Developments 98

    11.3.6 Key strategy 98

    11.4 Covis Pharma 99

    11.4.1 Company Overview 99

    11.4.2 Financial Overview 99

    11.4.3 Products/Services Offered 99

    11.4.4 SWOT Analysis 100

    11.4.5 Key Developments 100

    11.4.6 Key Strategy 100

    11.5 Ionis Pharmaceuticals 101

    11.5.1 Company Overview 101

    11.5.2 Financial Overview 101

    11.5.3 Products/Services Offered 101

    11.5.4 SWOT Analysis 102

    11.5.5 Key Developments 102

    11.5.6 Key Strategy 102

    11.6 ITF Pharma 103

    11.6.1 Company Overview 103

    11.6.2 Financial Overview 103

    11.6.3 Products/Services Offered 103

    11.6.4 Key Developments 103

    11.6.5 SWOT Analysis 103

    11.6.6 Key Strategy 103

    11.7 Mitsubishi Tanabe Pharma America 104

    11.7.1 Company Overview 104

    11.7.2 Financial Overview 104

    11.7.3 Products/Services Offered 105

    11.7.4 SWOT Analysis 105

    11.7.5 Key Developments 105

    11.7.6 Key strategy 105

    11.8 Mylan N.V. 106

    11.8.1 Company Overview 106

    11.8.2 Financial Overview 106

    11.8.3 Products/Services Offered 107

    11.8.4 SWOT Analysis 107

    11.8.5 Key Developments 107

    11.8.6 Key Strategy 107

    11.9 Sanofi 108

    11.9.1 Company Overview 108

    11.9.2 Financial Overview 108

    11.9.3 Products/Services Offered 108

    11.9.4 SWOT Analysis 109

    11.9.5 Key Developments 109

    11.9.6 Key Strategy 109

    11.10 Sun Pharmaceutical Industries Ltd 110

    11.10.1 Company Overview 110

    11.10.2 Financial Overview 110

    11.10.3 Products/Services Offered 110

    11.10.4 SWOT Analysis 111

    11.10.5 Key Development 111

    11.10.6 Key Strategy 111

    12 Appendix

    12.1 Discussion Blue Print 113

    13 List of Tables

    TABLE 1 MARKET SYNOPSIS 15

    TABLE 2 LIST OF ASSUMPTIONS 17

    TABLE 3 GLOBAL ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 34

    TABLE 4 GLOBAL ALS MARKET FOR SPORADIC ALS, BY REGION, 2020–2027 (USD MILLION) 35

    TABLE 5 GLOBAL ALS MARKET FOR FAMILIAL ALS, BY REGION, 2020–2027 (USD MILLION) 35

    TABLE 6 GLOBAL ALS MARKET FOR TREATMENT, 2020–2027 (USD MILLION) 37

    TABLE 7 GLOBAL ALS MARKET FOR MEDICATION, BY REGION, 2020–2027 (USD MILLION) 38

    TABLE 8 GLOBAL ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 38

    TABLE 9 GLOBAL ALS MARKET FOR PHYSICAL THERAPY, BY REGION, 2020–2027 (USD MILLION) 39

    TABLE 10 GLOBAL ALS MARKET FOR RESPIRATORY THERAPY, BY REGION, 2020–2027 (USD MILLION) 39

    TABLE 11 GLOBAL ALS MARKET FOR SPEECH THERAPY, BY REGION, 2020–2027 (USD MILLION) 40

    TABLE 12 GLOBAL ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 42

    TABLE 13 GLOBAL ALS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 43

    TABLE 14 GLOBAL ALS MARKET FOR SPECIALTY CENTERS, BY REGION, 2020–2027 (USD MILLION) 43

    TABLE 15 GLOBAL ALS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 44

    TABLE 16 GLOBAL ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 46

    TABLE 17 AMERICAS: ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 47

    TABLE 18 AMERICAS: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 48

    TABLE 19 AMERICAS: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 48

    TABLE 20 AMERICAS: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 48

    TABLE 21 AMERICAS: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 49

    TABLE 22 NORTH AMERICA: ALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 49

    TABLE 23 NORTH AMERICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 50

    TABLE 24 NORTH AMERICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 50

    TABLE 25 NORTH AMERICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 50

    TABLE 26 NORTH AMERICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 51

    TABLE 27 US: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 51

    TABLE 28 US: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 52

    TABLE 29 US: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 52

    TABLE 30 US: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 52

    TABLE 31 CANADA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

    TABLE 32 CANADA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 53

    TABLE 33 CANADA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 54

    TABLE 34 CANADA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 54

    TABLE 35 LATIN AMERICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

    TABLE 36 LATIN AMERICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 55

    TABLE 37 LATIN AMERICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 55

    TABLE 38 LATIN AMERICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 55

    TABLE 39 EUROPE: ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 56

    TABLE 40 EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

    TABLE 41 EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 57

    TABLE 42 EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 57

    TABLE 43 EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 58

    TABLE 44 WESTERN EUROPE: ALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59

    TABLE 45 WESTERN EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

    TABLE 46 WESTERN EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 60

    TABLE 47 WESTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 60

    TABLE 48 WESTERN EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 60

    TABLE 49 GERMANY: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

    TABLE 50 GERMANY: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 61

    TABLE 51 GERMANY: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 62

    TABLE 52 GERMANY: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 62

    TABLE 53 FRANCE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

    TABLE 54 FRANCE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 63

    TABLE 55 FRANCE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 63

    TABLE 56 FRANCE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 63

    TABLE 57 UK: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

    TABLE 58 UK: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 64

    TABLE 59 UK: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 65

    TABLE 60 UK: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 65

    TABLE 61 ITALY: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

    TABLE 62 ITALY: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 66

    TABLE 63 ITALY: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 66

    TABLE 64 ITALY: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 66

    TABLE 65 SPAIN: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

    TABLE 66 SPAIN: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 67

    TABLE 67 SPAIN: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 68

    TABLE 68 SPAIN: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 68

    TABLE 69 REST OF WESTERN EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

    TABLE 70 REST OF WESTERN EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 69

    TABLE 71 REST OF WESTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 69

    TABLE 72 REST OF WESTERN EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 69

    TABLE 73 EASTERN EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

    TABLE 74 EASTERN EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 70

    TABLE 75 EASTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 71

    TABLE 76 EASTERN EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 71

    TABLE 77 ASIA-PACIFIC: ALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72

    TABLE 78 ASIA-PACIFIC: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

    TABLE 79 ASIA-PACIFIC: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 73

    TABLE 80 ASIA-PACIFIC: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 73

    TABLE 81 ASIA-PACIFIC: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 74

    TABLE 82 JAPAN: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

    TABLE 83 JAPAN: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 75

    TABLE 84 JAPAN: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 75

    TABLE 85 JAPAN: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 75

    TABLE 86 AUSTRALIA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 76

    TABLE 87 AUSTRALIA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 76

    TABLE 88 AUSTRALIA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 77

    TABLE 89 AUSTRALIA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 77

    TABLE 90 CHINA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

    TABLE 91 CHINA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 78

    TABLE 92 CHINA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 78

    TABLE 93 CHINA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 78

    TABLE 94 INDIA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

    TABLE 95 INDIA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 79

    TABLE 96 INDIA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 80

    TABLE 97 INDIA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 80

    TABLE 98 SOUTH KOREA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

    TABLE 99 SOUTH KOREA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 81

    TABLE 100 SOUTH KOREA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 81

    TABLE 101 SOUTH KOREA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 81

    TABLE 102 REST OF ASIA-PACIFIC: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

    TABLE 103 REST OF ASIA-PACIFIC: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 82

    TABLE 104 REST OF ASIA-PACIFIC: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 83

    TABLE 105 REST OF ASIA-PACIFIC: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 83

    TABLE 106 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 84

    TABLE 107 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

    TABLE 108 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 85

    TABLE 109 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 85

    TABLE 110 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 86

    TABLE 111 MIDDLE EAST: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

    TABLE 112 MIDDLE EAST: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 87

    TABLE 113 MIDDLE EAST: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 87

    TABLE 114 MIDDLE EAST: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 87

    TABLE 115 AFRICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

    TABLE 116 AFRICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 88

    TABLE 117 AFRICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 89

    TABLE 118 AFRICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 89

    TABLE 119 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET: MAJOR PLAYER RANKING, 2020 91


    14 List of Figures

    FIGURE 1 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET: MARKET STRUCTURE 18

    FIGURE 2 RESEARCH PROCESS OF MRFR 20

    FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACHES 23

    FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET 25

    FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET 29

    FIGURE 6 VALUE CHAIN: GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET 31

    FIGURE 7 GLOBAL ALS MARKET, BY TYPE, 2020 AND 2027 (USD MILLION) 34

    FIGURE 8 GLOBAL ALS MARKET, BY TREATMENT, 2020 AND 2027 (USD MILLION) 37

    FIGURE 9 GLOBAL ALS MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 42

    FIGURE 10 GLOBAL ALS MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 46

    FIGURE 11 AMERICAS: ALS MARKET, BY REGION, 2020 (%) 47

    FIGURE 12 NORTH AMERICA: ALS MARKET, BY COUNTRY, 2020 (%) 49

    FIGURE 13 EUROPE: ALS MARKET, BY REGION, 2020 (%) 56

    FIGURE 14 WESTERN EUROPE: ALS MARKET, BY COUNTRY, 2020 (%) 58

    FIGURE 15 ASIA-PACIFIC: ALS MARKET, BY COUNTRY, 2020 (%) 72

    FIGURE 16 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY REGION, 2020 (%) 84

    Global Amyotrophic Lateral Sclerosis Treatment Market: Company Landscape


    The Global amyotrophic lateral sclerosis treatment market is dominated by several market players such as Mitsubishi Tanabe Pharma America, Sanofi, Mylan N.V., Covis Pharma, and others. The major players in the amyotrophic lateral sclerosis market are opting for new product launches, strategic collaborations, and partnerships to brace their position in the market.


    Mitsubishi Tanabe Pharma America is one of the leading players in the amyotrophic lateral sclerosis market. The company is a research-driven pharmaceutical company and offers RADICAVA (Edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS). Radicava is a free radical scavenger and slows the progression of ALS by removing free radicals in the nervous system. The company has successfully integrated small companies through mergers and acquisitions to build a strong supply chain network. High customer satisfaction level, exceptional performance in new markets, and strong brand portfolio add to the company’s competitive advantage.


    Sanofi is a key player owing to its product RILUTEK (Riluzole). RILUTEK is available as a capsule-shaped, film-coated tablet for oral administration containing 50 mg of Riluzole. The drug helps to slow down the worsening of this disease and prolong survival. Rilutek (Riluzole) was the first drug approved by the US Food and Drug Administration (FDA), in December 1995, to treat amyotrophic lateral sclerosis (ALS). It was originally developed by a French company, Rhone-Poulenc Rorer and is now marketed by Sanofi. Sanofi employs a strategy of maintaining the quality of products by maximum automation and rising investments on research and development which help the company in maintaining its market position. Additionally, the company is engaged in strategic collaborations which facilitates it to strengthen its position and expand its market presence globally.


    Covis Pharma is a renowned company in the amyotrophic lateral sclerosis market. The company operates in various business units and produces branded and generic pharmaceutical products and injectables in cardiovascular, central nervous system, oncology, and acute care markets. In April 2015, the company was acquired by Advanz Pharmaceuticals. The strategy of the company is to expand its generic and branded drugs business, thus bracing its position in the market.


    Mylan N.V. accounted is one of the prominent players operating in the global amyotrophic lateral sclerosis treatment market. The company’s global portfolio constitutes more than 7,500 marketed generic and branded generic, brand names, and OTC products around the world covering a wide range of therapeutic areas. The company is engaged in strategic collaborations and mergers which helps the company to hold its market position.


    Sun Pharmaceutical Industries Ltd delivers high quality and reasonable medicines trusted by customers in over 150 countries globally. The company aims to provide high-quality products to expand its generic business, and thus strengthen its position in the market.


    One of the prominent players in the market is ITF Pharma. The company is engaged in the development and sale of branded prescription and non-prescription pharmaceutical products. In September 2018, ITF Pharma announced the FDA approval of tiglutik (Riluzole) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS).


    Other key companies in the amyotrophic lateral sclerosis treatment market are Ascend Pharmaceuticals LLC and Apotex Inc.